Cancer stem cell biomarkers SOX2 and Oct4 in cervical cancer patients undergoing chemoradiotherapy

IF 1.4 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2024-02-25 DOI:10.1111/ajco.14049

Deep Chakrabarti, Sumaira Qayoom, Kirti Srivastava, Abigail Veravolu Resu, Divya Kukreja, Madhu Mati Goel, U. S. Singh, Naseem Akhtar, Shiv Rajan, Mranalini Verma, Rajeev Gupta, Madan Lal Brahma Bhatt

{"title":"Cancer stem cell biomarkers SOX2 and Oct4 in cervical cancer patients undergoing chemoradiotherapy","authors":"Deep Chakrabarti, Sumaira Qayoom, Kirti Srivastava, Abigail Veravolu Resu, Divya Kukreja, Madhu Mati Goel, U. S. Singh, Naseem Akhtar, Shiv Rajan, Mranalini Verma, Rajeev Gupta, Madan Lal Brahma Bhatt","doi":"10.1111/ajco.14049","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Cancer stem cell biomarkers SRY (sex-determining region Y)-box 2 (SOX2) and octamer-binding transcription factor 4 (Oct4) account for radioresistance in cervical squamous cell cancers (CSCCs). Their clinical implications are limited and contradictory.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this prospective cohort study, we recruited patients with FIGO IB2-IVA CSCC treated with primary chemoradiotherapy on regular follow-up. Tissue biopsy specimens were evaluated for SOX2 and Oct4 expression by immunohistochemistry, quantified by a product of proportion and intensity scores.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 59 patients were included. Most had a moderately differentiated (81%), keratinizing (59%) CSCC, and ≥FIGO stage IIB disease (95%). SOX2 expression (high:low 21:38 patients) and Oct4 expression (high:low 4:55 patients) had a significant interrelation (<i>p</i> = 0.005, odds ratio (95% CI) − 1.23 (1.004–1.520)). At a median follow-up of 36 months, the 3-year overall survival (OS) was 60% and 53% for low and high SOX2 expression (<i>p</i> = 0.856), and 54% and 100% for low and high Oct4 expression (<i>p</i> = 0.114). The 3-year disease-frese survival (DFS) was 65% and 50% in the low and high SOX2 expression (<i>p</i> = 0.259), and 59% and 75% for low and high Oct4 expression (<i>p</i> = 0.598). SOX2 expression was the only variable significantly associated with a lower OS and DFS on regression analysis.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our study demonstrated a trend toward improved OS and DFS with low SOX2 and high Oct4 expression in CSCC patients undergoing chemoradiotherapy.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cancer stem cell biomarkers SRY (sex-determining region Y)-box 2 (SOX2) and octamer-binding transcription factor 4 (Oct4) account for radioresistance in cervical squamous cell cancers (CSCCs). Their clinical implications are limited and contradictory.

Methods

In this prospective cohort study, we recruited patients with FIGO IB2-IVA CSCC treated with primary chemoradiotherapy on regular follow-up. Tissue biopsy specimens were evaluated for SOX2 and Oct4 expression by immunohistochemistry, quantified by a product of proportion and intensity scores.

Results

A total of 59 patients were included. Most had a moderately differentiated (81%), keratinizing (59%) CSCC, and ≥FIGO stage IIB disease (95%). SOX2 expression (high:low 21:38 patients) and Oct4 expression (high:low 4:55 patients) had a significant interrelation (p = 0.005, odds ratio (95% CI) − 1.23 (1.004–1.520)). At a median follow-up of 36 months, the 3-year overall survival (OS) was 60% and 53% for low and high SOX2 expression (p = 0.856), and 54% and 100% for low and high Oct4 expression (p = 0.114). The 3-year disease-frese survival (DFS) was 65% and 50% in the low and high SOX2 expression (p = 0.259), and 59% and 75% for low and high Oct4 expression (p = 0.598). SOX2 expression was the only variable significantly associated with a lower OS and DFS on regression analysis.

Conclusion

Our study demonstrated a trend toward improved OS and DFS with low SOX2 and high Oct4 expression in CSCC patients undergoing chemoradiotherapy.

Abstract Image

查看原文本刊更多论文

接受放化疗的宫颈癌患者的癌症干细胞生物标志物 SOX2 和 Oct4。

背景：癌症干细胞生物标志物SRY（性别决定区Y）-盒2（SOX2）和八聚体结合转录因子4（Oct4）是宫颈鳞状细胞癌（CSCC）放射抗性的原因。它们的临床意义有限且相互矛盾：在这项前瞻性队列研究中，我们招募了接受基础化放疗的 FIGO IB2-IVA CSCC 患者，并进行了定期随访。组织活检标本通过免疫组化方法评估SOX2和Oct4的表达，并用比例和强度评分的乘积进行量化：共纳入 59 例患者。大多数患者为中度分化（81%）、角化（59%）CSCC，病情≥FIGO IIB 期（95%）。SOX2表达（高：低21:38例患者）和Oct4表达（高：低4:55例患者）有显著的相互关系（P = 0.005，几率比（95% CI）- 1.23（1.004-1.520））。在中位随访36个月时，SOX2低表达和高表达患者的3年总生存率（OS）分别为60%和53%（p = 0.856），Oct4低表达和高表达患者的3年总生存率（OS）分别为54%和100%（p = 0.114）。SOX2低表达和高表达的3年无病生存率（DFS）分别为65%和50%（p = 0.259），Oct4低表达和高表达的3年无病生存率（DFS）分别为59%和75%（p = 0.598）。在回归分析中，SOX2表达是唯一与较低OS和DFS显著相关的变量：我们的研究表明，在接受放化疗的CSCC患者中，SOX2低表达和Oct4高表达有改善OS和DFS的趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.